When sequencing therapies for RRMM, how can we identify which patients may benefit most from CAR-T?

During the 2021 ASCO Annual Meeting and the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US. We asked, When sequencing therapies for relapsed/refractory multiple myeloma (RRMM), how can we identify which patients may benefit most from chimeric antigen receptor (CAR) T- cell therapy?

In this video, Munshi discusses the effectiveness and benefits of CAR T-cell therapy for different subsets of heavily pretreated patients with MM. However, he points out that all patients should be willing to adhere to the requirements of a CAR T-cell treatment program, including close follow-up and monitoring, and frequent clinic visits in the outpatient setting.